Amicus Therapeutics (FOLD) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

FOLD Amicus Therapeutics

Watchlist

9.650
+0.110+1.15%

Close Jan 23 16:00 ET

9.760
+0.110+1.14%

Post 17:45 ET

2.88BMarket Cap-28.38P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Is Amicus Therapeutics (FOLD) Among Billionaire Joseph Edelman's Long-Term Stock Picks?
Yahoo FinanceJan 20 14:58 ET
Amicus Therapeutics, Inc. (FOLD): The Biotech Stock With Biggest Upside Potential
Yahoo FinanceJan 17 11:19 ET
Cantor Fitzgerald Maintains Amicus Therapeutics(FOLD.US) With Buy Rating, Maintains Target Price $21
Moomoo NewsJan 15 08:31 ET · Ratings
Express News | Cantor Fitzgerald Reiterates Overweight on Amicus Therapeutics, Maintains $21 Price Target
BenzingaJan 15 07:50 ET
Positive Outlook for Amicus Therapeutics: Strong Galafold Performance and Strategic Expansion Plans for Future Growth
TipRanksJan 15 02:01 ET
Goldman Sachs Maintains Amicus Therapeutics(FOLD.US) With Hold Rating, Maintains Target Price $14
Moomoo NewsJan 14 11:32 ET · Ratings

Comments

Tonyco

Nov 24, 2024 18:26

$Amicus Therapeutics (FOLD.US)$
Enter 9.88 Exit 1 10.85 Exit 2 12.1 Exit 3 14.5
Stop loss according to risk

Meltyy

May 16, 2024 01:29

🔔 Perceptive Advisors Q1 ‘24* Holdings Released... 🐳

» Holdings: 112
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...

Moomoo AI

Feb 7, 2024 06:42

Despite Amicus Therapeutics' recent share price uptick and steady revenue growth, the market's high expectations are reflected in the share price fall over the past three years. The company's 3.2% total shareholder return over the last twelve months falls short of the market return.

Strong Week for Amicus Therapeutics (NASDAQ:FOLD) Shareholders Doesn't Alleviate Pain of Three-year Loss

Moomoo AI

Jan 3, 2024 05:28

Investors might overlook Amicus Therapeutics' below industry-level growth forecast, risking future disappointment if the P/S ratio falls in line with the growth outlook. Moderate P/S ratio poses a risk as weaker revenue outlook might lead to share price drop.

Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) Shares Climb 28% But Its Business Is Yet to Catch Up

Mini0n

Sep 28, 2023 11:13

$Amicus Therapeutics (FOLD.US)$ Good thing this didn't have any bad news, jesus

FOLD Amicus Therapeutics

Trade Overview

Capital Trend

News

Comments

Trending Stocks